Nicolau syndrome

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

No FDA or trial events recorded yet for Nicolau syndrome.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

Patient Assistance Programs1

Avonex

Biogen, Inc.

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

3 FDA-approved

XARELTO

(RIVAROXABAN)standard

Janssen Pharmaceuticals, Inc.

Factor Xa Inhibitor [EPC]

12.1 Mechanism of Action XARELTO is a selective inhibitor of FXa. It does not require a cofactor (such as Anti-thrombin III) for activity. Rivaroxaban...

FDA label ↗

Copaxone

(glatiramer acetate)Orphan drugstandard

Teva Pharmaceuticals USA

12.1 Mechanism of Action The mechanism(s) by which glatiramer acetate exerts its effects in patients with MS are not fully understood. However, glatir...

FDA label ↗

Avonex

(Interferon beta-1a)Orphan drugstandard

Biogen, Inc.

Interferon beta [EPC]

12.1 Mechanism of Action The mechanism of action by which AVONEX exerts its effects in patients with multiple sclerosis is unknown.

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Nicolau syndrome.
Search all trials →
Search clinical trials for Nicolau syndrome

Recent News & Research

No recent news articles indexed yet for Nicolau syndrome.
Search PubMed for Nicolau syndrome

Browse all Nicolau syndrome news →

Specialist Network

Top 2 by expertise

View all Nicolau syndrome specialists →

Quick Actions